PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Gauges a company's environmental, social, and governance practices.
47.09
ESG score below 80% of Biotechnology median of 60.13. Michael Burry would check for potential stranded assets and regulatory compliance issues.
27.98
Environmental score below 80% of Biotechnology median of 57.86. Michael Burry would check for potential carbon tax exposure and regulatory compliance costs.
55.14
Social score 80-90% of Biotechnology median of 63.12. Martin Whitman would look for hidden social liabilities and reputational risks.
58.16
Governance score near Biotechnology median of 61.20. David Dodd would investigate if industry-standard governance adequately protects shareholder interests.